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esponsibility of InstAbstract Non-steroidal anti-inﬂammatory drugs (NSAIDs) have been successfully used for the
alleviation of pain and inﬂammation in the past and continue to be used daily by millions of patients
worldwide. However, gastrointestinal (GI) toxicity associated with NSAIDs is an important medical and
socioeconomic problem. Local generation of various reactive oxygen species plays a signiﬁcant role in the
formation of gastric ulceration associated with NSAIDs therapy. Co-medication of antioxidants along with
NSAIDs has been found to be beneﬁcial in the prevention of GI injury. This paper describes the synthesis
and biological evaluation of N-1-(phenylsulfonyl)-2-methylamino-substituted-1H-benzimidazole deriva-
tives as anti-inﬂammatory analgesic agents with lower GI toxicity. Studies in vitro and in vivo
demonstrated that the antioxidant activity of the test compounds decreased GI toxicity.
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NSAIDs are among the most commonly prescribed drugs world-
wide. Because of their ‘over-the-counter’ availability, they are also
consumed on non-prescription basis as well. However, their intake
is frequently associated with gastrointestinal (GI) side effects,
representing an important medical and socioeconomic problem1.
These drugs can affect all segments of the GI tract and be
responsible for ulceration, dyspepsia or gastric bleeding. In some
cases, they can cause serious toxicity requiring hospital admission
and aggressive management2.
It is well known that local generation of reactive oxygen species
plays an important role in the formation of gastric ulceration
associated with NSAIDs therapy3,4. Thus, co-medication of NSAIDs
with antioxidants could be a useful approach to overcome gastric side
effects. Some very early studies have suggested the beneﬁcial role of
vitamin C and vitamin E in NSAIDs-induced GI side effects5.
However, drug interactions with vitamin E may result in additive
blood thinning effects of NSAIDs and vitamin C can raise the level of
NSAIDs in the blood by increasing their stay in the body and make
them less appealing as a therapeutic strategy6. Therefore, as an
alternative approach, anti-inﬂammatory analgesics with potent anti-
oxidant activity are a potential therapeutic strategy for treatment of
pain and inﬂammatory disorders without GI side effects.
The benzimidazole moiety represents an important pharmacophore and
privileged structure in medicinal chemistry. Recently, benzimidazole has
emerged as pharmacophore of choice for designing anti-inﬂammatory
analgesic molecules7,8. In addition, the literature shows that benzimidazole
derivatives substituted at the 1 and 2 positions exhibit potent antioxidant
activity9–11. Moreover, 1, 2-substituted benzimidazole derivatives as proton
pump inhibitors have shown their gastroprotective action, irrespective of
their acid suppressive action12. This has prompted us to explore N-1-
(phenylsulfonyl)-2-methylamino-substituted-1H-benzimidazole derivatives
as gastroprotective anti-inﬂammatory and analgesic agents. The synthesized
compounds were evaluated for their anti-inﬂammatory, analgesic activity
along with their gastroprotective mechanism of action by in vitro and
in vivo assays.2. Results and discussion
2.1. Synthesis
The present research work was carried out to search for novel
benzimidazole derivatives as anti-inﬂammatory analgesics with
low ulcerogenic potential. The sequence of the reactions employed
for the synthesis of novel benzimidazole derivatives is outlined in
Scheme 1. Compound 1 was prepared according to literature
procedures starting from o-phenylenediamine13. Sulfonylation of
compound 1 was done in the presence of dry pyridine and
benzenesulfonyl chloride to give compound 214. FromScheme 1 Synthetic route of compounds 3a–i. Reagent A: (i) benzenesu
iodide and (ii) potassium hydroxide.compound 2, novel benzimidazole derivatives 3a–i were synthe-
sized by adding different substituted aryl amines. The purity of the
compounds was accomplished by column chromatographic separa-
tion using silica gel as the stationary phase and chloroform:
methanol (9:1) as the mobile phase.2.2. Biological assays
The newly synthesized N-1-(phenylsulfonyl)-2-methylamino-sub-
stituted-1H-benzimidazole derivatives were screened in vivo in
order to evaluate their pharmacological activity. The test com-
pounds were evaluated for their anti-inﬂammatory activity by
evaluating carrageenan-induced paw edema in rats. Compounds
3a–i were found to exhibit encouraging anti-inﬂammatory activity
ranging from 23.88% to 37.31% and the results are summarized in
Table 1. It was observed that the tested compounds 3d, 3e, 3f and
3i showed signiﬁcant reduction in edema (31.34%, 32.84%,
34.33% and 37.31%, respectively) after 3 h when administered
at doses of 100 mg/kg p.o. Further, all the compounds were
assessed for their analgesic activity by using acetic acid induced
writhing test in mice and the results are given in Table 2. The test
compounds 3d, 3e, 3f and 3i demonstrated 54.03%, 52.84%,
53.55% and 57.58% protection in the number of writhes produced
by acetic acid, which are comparable to the standard drug acetyl
salicylic acid. These results showed a positive contribution of
electron donating substituents towards anti-inﬂammatory as well
as analgesic activity. This is in accord with published reports,
which demonstrate that substitutions with electron donating groups
enhance the lipophilicity of the molecule15,16, which in-turn may
be responsible for signiﬁcant anti-inﬂammatory and analgesic
activities for tested compounds 3d, 3e, 3f and 3i.
The newly synthesized compounds are designed with an aim to
identify gastroprotective anti-inﬂammatory and analgesic agents.
Oxidative stress is an important component involved in the
pathophysiology of NSAIDs-induced GI ulceration. This is further
supported by the ﬁnding that indomethacin administration results
in increased reactive oxygen species production in the gastric
mucosa, followed by gastric ulceration17. Chemical modiﬁcation
of existing NSAIDs with electron donating substitutions will lead
to molecules with potent antioxidant activity, which in turn may
lead to GI-safe NSAIDs. In the present study, the gastroprotective
potential of the newly synthesized derivatives and the mechanism
of action for better gastric tolerance were studied. The in vitro
antioxidant potential of all the synthesized compounds was
assessed by the ferric reducing antioxidant power (FRAP) assay.
From the results, it is observed that compounds 3d, 3e, 3f and 3i
with electron donating substituents were the most efﬁcient
compounds in the FRAP assay (Fig. 1). After the in vitro
antioxidant activity, the test compounds were studied for transla-
tion of their in vitro activity to an in vivo effect–i.e., better gastriclfonylchloride and (ii) dry pyridine; Reagent B: (i) ethanol, potassium
Table 1 Anti-inﬂammatory activity of 3a–i and indomethacin.















aStatistically signiﬁcant compared to control group (Pr0.05);
data was analyzed by unpaired one-way ANOVA test.
Table 2 Analgesic activity of 3a–i and acetyl salicylic acid.














Acetyl salicylic acida 25.6771.45 63.51a
aStatistically signiﬁcant compared to control (Pr0.05).
Figure 1 Ferric reducing antioxidant power of test compounds 3a–i
and ascorbic acid. “*” Statistically signiﬁcant (Pr0.05) as compared
to blank.
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potential to produce GI-injury and level of thiobarbituric acid
reactive substances (TBARS) in the gastric mucosa was studied as
an index of oxidative stress. Oral administration of indomethacin
produced gastric hemorrhagic erosions and increased the levels of
TBARS in the gastric mucosa, whereas, administration of an
equipotent dose of test compounds 3d, 3e, 3f and 3i producessigniﬁcantly lower gastric ulceration as compared to indomethacin.
The level of TBARS with the test compounds was found to be
signiﬁcantly lower, suggestive of lower oxidative stress, which is
closely parallel to lesser gastric mucosal injury as compared to
indomethacin. From the above discussion, the increased gastric
tolerability of the tested compounds can be attributed to their
antioxidant properties. The gastroprotective activity results of test
compounds 3a–i are depicted in Table 3.3. Conclusions
NSAIDs-induced gastric toxicity is common and associated with
serious adverse effects which affect all segments of the GI tract.
Reactive oxygen species play an important role in the pathogenesis
of gastric mucosal injury induced by NSAIDs such as indometha-
cin18. Co-administration of antioxidants like vitamin C and
vitamin E with NSAIDs has been found by others to inhibit the
pathological changes induced by NSAIDs and these combinations
have shown protective action. However, unwanted drug interac-
tions of these antioxidants with NSAIDs limit their therapeutic
usefulness. Therefore, as an alternative approach, chemical deri-
vatization of existing NSAIDs that will lead to molecules with
potent antioxidant activity may be a useful approach to ﬁnd safer
and potent NSAIDs, provided that the molecular modiﬁcations do
not abolish the anti-inﬂammatory analgesic activity. In the present
study, we have reported a series of novel benzimidazole deriva-
tives as anti-inﬂammatory analgesic agents with inherent antiox-
idant activity. The therapeutic utility of these derivatives as GI
tolerable anti-inﬂammatory, analgesic agents and their mechanism
of action were established by in vitro and in vivo studies. The
results suggested that these derivatives might serve as interesting
lead compounds and could revolutionize the future development of
GI-safe anti-inﬂammatory analgesic agents.4. Experimental protocols
All chemicals were purchased from Sigma-Aldrich and Lancaster Co.
as495% pure and used as such without further puriﬁcation. The
solvents, except for LR grade, were dried as per literature if
necessary. The progress of chemical reactions was monitored by thin
layer chromatography on pre-coated silica gel plates using the iodine
chamber as a detector. Melting points of all compounds were
determined using an open capillary tube method, and were uncor-
rected. The IR spectra were recorded on Bruker Alpha-FT-IR
spectrophotometer, 1H and 13C NMR spectra on a Bruker Avance
DPX-200 (400 MHz), mass spectra on Waters Q-TOF micro LC-MS
spectrometer at ESI (þ) mode and CI mode. Elemental analysis was
performed on Leco CHNS-932 (Leco, St. Joseph, USA).
4.1. Chemistry
Synthesis of compound 1 and intermediate compound 2 was
carried out according to procedures reported in the literature13,14.
Novel benzimidazole derivatives 3a–i were synthesized as follows.
4.1.1. Synthesis of N-1-(phenylsulfonyl)-2-methylamino-substituted-
1H-benzimidazole derivatives 3a–i
For the synthesis of the benzimidazole derivatives, potassium
iodide (2 g, 0.012 mol) and potassium hydroxide (1 g, 0.017 mol)
in dry ethanol was added to a solution of compound 2 (2 g,
Table 3 Gastroprotective activity of test compounds 3a–i.















aStatistically signiﬁcant compared to Indomethacin (Pr0.05).
Monika Gaba et al.3400.006 mol), with different substituted aryl amines and reﬂuxed for
12 h. The mixture was poured into ice-cold water. The precipitates
formed were vacuum-ﬁltered, washed, dried and recrystallized
using hot water and ethanol.4.1.2. N-((1-(phenylsulfonyl)-1H-benzo[d]imidazole-2-yl)methyl)
benzenamine 3a
Yield: 57%; m.p. 226–228 1C; UV (ethanol) λmax: 284 nm; FTIR:
υmax (cm
–1), 3389.98 (NH), 2962.86, 2920.43 (CH-aromatic),
1515.82 (C¼C-aromatic), 1317.36 (CN), 1026.97, 884.30
(S¼O); 1H NMR (CDCl3): δ 2.16 (s, 2H), 5.40 (s, NH), 6.87
(m, 4H), 6.89–7.35 (m, 5H), 7.43–7.56 (m, 5H); 13C NMR
(CDCl3): δ 147.60, 141.54, 138.97, 137.98, 133.80, 131.11,
129.80, 128.36, 123.08, 117.21, 115.30, 113.50, 36.10; Anal.
Calcd. for C20H17N3O2S: C, 66.10; H, 4.71; N, 11.56, Found: C,
66.01; H, 4.61; N, 11.45.4.1.3. 3-Nitro-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazol-2-yl)
methyl)benzenamine 3b
Yield: 59%; m.p. 228–230 1C; UV (ethanol) λmax: 255 nm; FTIR:
υmax (cm
–1), 3426.30 (NH), 3067.84, 3202.91 (CH-aromatic),
1616.81 (C¼C-aromatic), 1083.75, 1004.62, 809.84, 866.70
(S¼O), 1513.57 (NO2), 1339.08 (CN); 1H NMR (DMSO-d6): δ
2.10 (s, 2H), 3.43 (s, NH), 7.17–7.25 (m, 5H), 7.28–7.34 (m, 2H),
7.43–7.44 (m, 2H), 7.60–7.62 (m, 3H), 8.01 (s, H,); 13C NMR
(DMSO-d6): δ 149.20, 148.51, 141.50, 138.97, 137.98, 133.80,
131.11, 130.50, 129.80, 128.36, 123.08, 119.60, 115.30, 109.51,
107.62, 36.10; Anal. Calcd. for C20H16N4O4S: C, 58.81; H, 3.95;
N, 13.72, Found: C, 58.72; H, 3.80; N, 13.60.4.1.4. 4-Nitro-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazol-2-yl)
methyl)benzenamine 3c
Yield: 52%; m.p. 202–204 1C; UV (ethanol) λmax: 399 nm; FTIR:
υmax (cm
–1), 3426.16 (NH), 2964.01 (CH-aromatic), 1513.57
(C¼C-aromatic), 1339.08 (CN), 1513.57 (CH2), 1122.76,
886.70, 809.84 (S¼O), 1513.57, 1339.08 (NO2); 1H NMR
(DMSO-d6): δ 2.08 (s, 2H), 3.44 (s, NH), 6.57 (d, 2H, J¼9.6 Hz),
7.17–7.29 (m, 5H), 7.57 (d, 2H, J¼6.9 Hz), 7.74–7.76 (m, 2H),
7.86 (d, 2H, J¼8.2 Hz); 13C NMR (DMSO-d6): δ 153.70, 141.50,
138.97, 137.98, 136.89, 133.80, 131.11, 129.80, 128.36, 123.08,
121.91, 115.30, 114.40, 36.10.4.1.5. 2-Methyl-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazole-2-
yl)methyl)benzenamine 3d
Yield: 50%; m.p. 219–220 1C; UV (ethanol) λmax: 284 nm; FTIR:
υmax (cm
1), 3316.29 (NH), 3061.51, 3027.81 (CH-aromatic),
1500.49 (C¼C-aromatic), 1372.19, 1625.37 (CN), 1445.79,
2918.85 (CH3), 1076.39, 1028.90, 873.24 (S¼O); 1H NMR
(CDCl3): δ 2.25 (s, 3H), 2.56 (s, 2H), 5.4 (s, NH), 6.84–6.86
(m, 2H), 6.95 (d, 2H, J¼7.2 Hz), 7.05–7.08 (m, 4H), 7.19–7.31
(m, 5H); 13C NMR (CDCl3): δ 146.51, 141.54, 138.97, 137.98,
133.80, 131.11, 129.80, 128.36, 126.21, 123.08, 117.21, 115.03,
113.40, 36.41, 15.50; Anal. Calcd. for C21H19N3O2S: C, 66.82; H,
5.07; N, 11.13, Found: C, 66.70; H, 5.15; N, 11.01.
4.1.6. 3-Methyl-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazol-2-
yl)methyl)benzenamine 3e
Yield: 53%; m.p. 213–215 1C; UV (ethanol) λmax: 285 nm; FTIR:
υmax (cm
–1), 3393.60 (NH), 3058.78, 2958.81 (CH-aromatic),
1515.98 (C¼C-aromatic), 1485.07, 1644.97 (CN), 1397.04
(CH3), 1074.59 (S¼O); 1H NMR (CDCl3): δ 2.21 (3H, s), 2.53
(2H, s), 5.1 (1NH, s), 6.01 (1H, s), 6.74 (3H, m), 7.04–7.08 (2H,
m), 7.20–7.31 (5H, m), 7.44–7.51 (2H, d, J¼6.8 Hz); 13C NMR
(CDCl3): δ 147.60, 141.54, 139.20, 138.97, 137.98, 133.80,




Yield: 50%; m.p. 221–223 1C; UV (ethanol) λmax: 223 nm; FTIR:
υmax (cm
–1), 3421.34 (NH), 3003.79, 3056.78 (CH-aromatic),
1646.67 (C¼C-aromatic), 1083.11, 992.80 (S¼O), 2867.18 (CH3);
1H NMR (CDCl3): δ 2.21 (s, 3H), 2.48 (s, 2H), 4.50 (s, NH), 6.60 (d,
2H, J¼8.5 Hz), 6.93 (d, 2H, J¼8.0 Hz), 7.20–7.30 (m, 5 H), 7.46–
7.52 (m, 4H); 13C NMR (CDCl3): δ 144.60, 141.54, 138.97, 137.98,
133.80, 131.11, 129.80, 128.36, 126.80, 123.08, 115.30, 113.50,
36.10, 24.31; Exact Mass: 377 Mol. Wt.: 377 m/z: 377 (16.0%), 378
(17.0%), 379 (24.0%), 376 (12.0%), 362 (8.0%).
4.1.8. 3,5-Dichloro-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazol-
2-yl)methyl)benzenamine 3g
Yield: 49%; m.p. 240–242 1C; UV (ethanol) λmax: 347 nm; FTIR:
υmax (cm
–1), 3306.58 (NH), 3068.25, 2959.21 (CH-aromatic),
1596.31 (C¼C-aromatic), 1303.17 (CN), 1449.09 (CH),
1074.99, 1027.58 (S¼O), 797.04 (CCl); 1H NMR (CDCl3): δ
2.77 (s, 2H), 4.57 (s, NH), 6.49 (d, 2H, J¼1.76 Hz), 6.67 (s, H),
7.17–7.31 (m, 5H), 7.47–7.50 (m, 4H); 13C NMR (CDCl3): δ
150.40, 141.54, 138.97, 137.98, 133.80, 131.11, 129.80, 128.36,
123.08, 118.80, 115.30, 112.01, 36.10; Anal. Calcd. for
C20H15Cl2N3O2S: C, 55.56; H, 3.50; N, 9.72, Found: C, 55.45;
H, 3.59; N, 9.60.
4.1.9. 2,6-Dichloro-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazol-2-
yl)methyl)benzenamine 3 h
Yield: 50%; m.p. 217–219 1C; UV (ethanol) λmax: 295 nm; FTIR:
υmax (cm
–1), 3427.64 (NH), 3045.47 (CH-aromatic), 1570.04,
1520.59 (C¼C-aromatic), 1261.91, 1216.04 (CN), 1013.51,
891.73, 804.88, 1148.14 (S¼O), 732.30 (CCl); 1H NMR (CDCl3):
δ 2.23 (s, 2H), 4.44 (s, NH), 6.59–6.63 (t, 1H, J¼8 Hz), 7.15–7.33
(m, 9H), 7.49 (d, 2H, J¼10.2 Hz); 13C NMR (CDCl3): δ 144.31,
141.54, 138.97, 137.98, 133.80, 131.11, 129.80, 128.36, 127.87,
123.08, 120.01, 115.30, 35.10. Exact Mass: 431 Mol. Wt.: 431 m/
z: 431 (1.0%), 432 (10.0%), 433 (4.0%), 434 (2.0%).
Benzimidazole derivatives for GI-friendly anti-inﬂammatory analgesic agents 3414.1.10. 3,4-Dimethyl-N-((1-(phenylsulfonyl)-1H-benzo[d]imidazol-
2-yl)methyl)benzenamine 3i
Yield: 58%; m.p. 239–240 1C; UV (ethanol) λmax: 235 nm; FTIR:
υmax (cm
–1), 3393.69 (NH), 3058.10, 3008.30 (CH-aromatic),
1515.17 (C¼C-aromatic), 1216.47, 1339.76 (CN), 2959.72
(CH3), 995.76 (S¼O); 1H NMR (CDCl3): δ 2.11 (s, 6H,), 2.46
(s, 2H), 3.09 (s, NH), 6.95–6.99 (m, 3H), 7.20–7.32 (m, 4H),
7.44–7.91 (m, 5H); 13C NMR (CDCl3): δ 144.50, 141.54, 138.97,
137.98, 133.80, 131.11, 129.80, 128.36, 125.31, 123.08, 115.30,
113.50, 110.40, 36.10, 17.8; Anal. Calcd. for C22H21N3O2S: C,
67.50; H, 5.41; N, 10.73, Found: C, 67.38; H, 5.30; N, 10.60.
4.2. Pharmacology
Sprague-Dawley (SD) rats of either sex weighing 180–250 g were
used to study anti-inﬂammatory activity and ulcerogenic activity
of the test compounds. Albino mice of either sex weighing 20–
25 g were used for evaluation of analgesic activity. All the
experimental procedures used in this study were approved by the
Institutional Animal Ethical Committee (IAEC), registered under
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), Government of India.
Animals were housed individually in polypropylene cages, main-
tained under standard conditions of alternating 12 h light-and-dark
cycles at a constant temperature (2572 1C and 35%–60% relative
humidity). Animals were fed with standard rat pellet diet (Hindu-
stan Lever Ltd., Mumbai, India) and water ad libitum.
4.3. Anti-inﬂammatory activity
The anti-inﬂammatory activity of the test compounds was carried
out by using the carrageenan-induced rat paw edema model,
employing 0.1 mL of 1.0% carrageenan solution as the phlogistic
agent19. SD rats of either sex were randomized into vehicle control,
standard and different test groups of six rats each. The 2% sodium
carboxy methylcellulose (CMC) served as vehicle control and
indomethacin was used as the standard drug at the dose level of
50 mg/kg body weight. The test compounds were administered p.o.
as a suspension in 2% sodium CMC, at a dose level of 100 mg/kg
body weight, 30 min before the injection of the phlogistic agent.
The paw edema volume was measured with the help of a
plethysmograph by the mercury displacement method at 0 h
(immediately after injection) and 3 h (post injection of carrageenan).
The edema (%) is shown in Table 1. The percent anti-inﬂammatory
activity was calculated according to the formula as given below:
Edema ð%Þ ¼ 100 1V t=Vc
  100 ð1Þ
Reduction in edema %ð Þ ¼ 1V t=Vc
  100 ð2Þ
Vt and Vc is the edema volume in drug-treated and control
groups, respectively.
4.4. Analgesic activity
The test compounds 3a–i were evaluated for their analgesic
activity by using acetic acid induced writhing method20. Albino
mice of either sex (2025 g, body weight) were randomized into
vehicle control, standard and test groups of six mice each. After
randomization, the control group mice were administered 2%
sodium CMC, acetyl salicylic acid (standard drug) or compounds
3a–i at a dose of 100 mg/kg orally. After 30 min of dosing, aceticacid solution (0.6% v/v in distilled water) was administered i.p. at a
dose of 1 mL/kg. The number of writhes in each animal was
recorded for 15 min. The analgesic activity was expressed as
percentage of protection and the results are presented in Table 2.
Protection ð%Þ ¼ 100 V t=V c
  100 ð3Þ
4.5. In vitro antioxidant activity
The in vitro antioxidant activity of compounds 3a–i was performed
by FRAP assay based on the reduction of a colorless
Fe3þ-tripyridyltriazine complex into a blue-colored Fe2þ-tripyri-
dyltriazine complex by the action of electron-donating antioxi-
dants21. The working FRAP reagent was prepared by mixing 10 mL
of sodium acetate buffer (pH¼3.6) with 1 mL of TPTZ (2,4,6-tri(2-
pyridyl)-1,3,5-triazine) solution and 1 mL FeCl3  6H2O (10:1:1, v/v/
v, respectively). The FRAP reagent was warmed to 37 1C before
being used and the assay was started by adding 228 μL of FRAP
reagent into a 96-well microtiter-plate, followed by ascorbic acid
(200 μmol/L) as a standard and test compounds (1 mmol/L). The
blank was 12 μL of methanol. The reaction was allowed to run for
30 min and absorbance (Abs) was read at 593 nm. The experiments
were performed in triplicate and their mean was calculated for each
compound. The absorbance change was translated into FRAP value
(μmol/L) by the following formula:
FRAP value¼ ½ðAbsSample30 min–AbsblankÞ=ðAbsStandard30 min–AbsblankÞ
Concstandard ð4Þ
where ferrous sulfate was used as standard (200 μmol/L).
4.6. Gastric ulcerogenic potential and gastric lipid peroxidation
NSAIDs like indomethacin induce gastric lesions in experimental
animals by impairing barrier properties of the mucosa and
suppression of gastroprotective prostaglandin (PGE2 and PGI2)
synthesis. The test compounds 3a–i were tested for their gastric
ulcerogenic potential. SD rats of either sex weighing 180–250 g
were divided into vehicle control, standard and different test
compound groups (n¼6). The test compounds and indomethacin
were administered orally in 2% sodium CMC orally at the
dose levels of 100 and 50 mg/kg, respectively. After 6 h, the rats
were sacriﬁced by cervical dislocation and their stomachs
were removed. The stomachs were opened along the greater
curvature and examined under 3-fold magniﬁcation. The length
of the longest diameter of the lesions was measured and summated
to give a total lesion score (in mm) for each animal22. Mean count
for each group was calculated and is given in Table 3.
After measuring the lesions, the mucosa of the stomachs was
scraped with glass slides and the concentration of TBARS, an
index of oxidative stress, was measured according to Ohkawa
et al.23. 1,1,3,3-Tetramethoxy propane was used as an external
standard and the concentration of the TBARS was expressed as
(nmol/mL)/mg protein23.
4.7. Statistical analysis
Statistical analysis of the pharmacological activity of the synthe-
sized compounds was performed by one-way analysis of variance
(ANOVA) followed by Tukey's test. The P value of less than 0.05
was considered statistically signiﬁcant. All values were expressed
Monika Gaba et al.342as mean7SEM (standard error of the mean). SIGMASTAT,
version 2.0 by Jandel Corporation was used for statistical analysis.Acknowledgments
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